聚合酶Ⅰ和转录本释放因子：一个具有脂质代谢和免疫微环境重构功能的全新胶质瘤标记物

崔晓腾; 康春生

doi:10.12354/j.issn.1000-8179.2022.20220128

聚合酶Ⅰ和转录本释放因子：一个具有脂质代谢和免疫微环境重构功能的全新胶质瘤标记物

doi: 10.12354/j.issn.1000-8179.2022.20220128

崔晓腾,
康春生^,

天津医科大学总医院，天津市神经病学研究所神经肿瘤研究室（天津市300052）

基金项目: 本文课题受国家自然科学基金（编号：82073322）和天津市重点研发计划科技支撑项目（编号：20YFZCSY00360）资助

详细信息

作者简介:
崔晓腾：专业方向为胶质母细胞瘤代谢重编程和免疫微环境机制研究

通讯作者:
康春生 kang97061@tmu.edu.cn

计量
- 文章访问数: 218
- HTML全文浏览量: 43
- PDF下载量: 37
- 被引次数: 0
出版历程
- 收稿日期: 2022-01-21
- 录用日期: 2022-03-18
- 网络出版日期: 2022-07-11

Polymerase-1 and transcript release factor: a novel glioma marker with functions of lipid metabolism and immune microenvironment remodeling

Xiaoteng Cui,
Chunsheng Kang^,

Lab of Neuro-oncology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin 300052, China

Funds: This work was supported by the National Natural Science Foundation of China (No. 82073322) and Technology Support Project of Tianjin Key R&D Program (No. 20YFZCSY00360)

More Information

Corresponding author: Chunsheng Kang; E-mail: kang97061@tmu.edu.cn

摘要

摘要: 聚合酶Ⅰ和转录本释放因子（polymerase-1 and transcript release factor，PTRF/Cavin-1），最初因参与基因转录终止过程被报道，随后发现其可与细胞膜上小凹蛋白结合，通过参与细胞质膜小凹形成促进外泌体分泌，调节全身脂质代谢等。先天性全身性脂肪营养不良患者常见PTRF/Cavin-1基因突变/缺失。在胶质瘤中，PTRF/Cavin-1不仅可作为提示患者预后的标记物，还可通过影响肿瘤细胞内吞和外分泌、肿瘤脂质代谢重编程、重塑肿瘤细胞外基质等多种途径促进肿瘤恶性行为发生。本文归纳整理了PTRF/Cavin-1在胶质瘤中的多功能性，有助于全面理解其促进肿瘤发展的分子机制，开发针对PTRF/Cavin-1的胶质瘤靶向药物。
- 胶质瘤 /
- PTRF/Cavin-1 /
- 细胞内吞 /
- 脂质代谢 /
- 免疫微环境
Abstract: Polymerase-1 and transcript release factor (PTRF, also known as Cavin-1) was first reported to be involved in gene transcription termination. Binding of PTRF/Cavin-1 to caveolin on the cell membrane was recently demonstrated, as was its participation in various functions, including the promotion of exosome secretion via caveolae formation and regulation of systemic lipid metabolism. PTRF/Cavin-1 gene mutation or deletion is commonly found in patients diagnosed with congenital generalized lipodystrophy. In glioma, PTRF/Cavin-1 has been identified as a marker for the prognosis of patients and promotes tumor malignant behavior by affecting endocytosis and exocrine secretion, reprogramming tumor lipid metabolism, remodeling extracellular matrix, and other functions. This review summarizes the versatility of PTRF/Cavin-1 in glioma. The information will be helpful for the comprehensive understanding of the molecular mechanism of PTRF/Cavin-1 in promoting tumorigenesis and in the development of PTRF/Cavin-1 targeted drugs for precise treatment of glioma.
- glioma /
- polymerase-1 and transcript release factor (PTRF/Cavin-1) /
- endocytosis /
- lipid metabolism /
- immune microenvironment

HTML全文

参考文献(29)

[1]	Jiang T, Nam DH, Ram Z, et al. Clinical practice guidelines for the management of adult diffuse gliomas[J]. Cancer Lett, 2021, 499:60-72. doi: 10.1016/j.canlet.2020.10.050
[2]	Huang LE. Friend or foe-IDH1 mutations in glioma 10 years on[J]. Carcinogenesis, 2019, 40(11):1299-1307. doi: 10.1093/carcin/bgz134
[3]	Yu W, Zhang LL, Wei QC, et al. O6-methylguanine-DNA methyltransferase (MGMT): challenges and new opportunities in glioma chemotherapy[J]. Front Oncol, 2020, 9:1547. doi: 10.3389/fonc.2019.01547
[4]	Jansa P, Mason SW, Hoffmann-Rohrer U, et al. Cloning and functional characterization of PTRF, a novel protein which induces dissociation of paused ternary transcription complexes[J]. EMBO J, 1998, 17(10):2855-2864. doi: 10.1093/emboj/17.10.2855
[5]	Hill MM, Bastiani M, Luetterforst R, et al. PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function[J]. Cell, 2008, 132(1):113-124. doi: 10.1016/j.cell.2007.11.042
[6]	Wang L, Yang C, Wang QX, et al. Homotrimer cavin1 interacts with caveolin1 to facilitate tumor growth and activate microglia through extracellular vesicles in glioma[J]. Theranostics, 2020, 10(15):6674-6694. doi: 10.7150/thno.45688
[7]	Jansa P, Burek C, Sander EE, et al. The transcript release factor PTRF augments ribosomal gene transcription by facilitating reinitiation of RNA polymerase I[J]. Nucleic Acids Res, 2001, 29(2):423-429. doi: 10.1093/nar/29.2.423
[8]	Parton RG, Tillu VA, Collins BM. Caveolae[J]. Curr Biol, 2018, 28(8):R402-R405. doi: 10.1016/j.cub.2017.11.075
[9]	Liu LB, Brown D, McKee M, et al. Deletion of Cavin/PTRF causes global loss of caveolae, dyslipidemia, and glucose intolerance[J]. Cell Metab, 2008, 8(4):310-317. doi: 10.1016/j.cmet.2008.07.008
[10]	Liu LB, Pilch PF. A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization[J]. J Biol Chem, 2008, 283(7):4314-4322. doi: 10.1074/jbc.M707890200
[11]	Hayashi YK, Matsuda C, Ogawa M, et al. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy[J]. J Clin Invest, 2009, 119(9):2623-2633. doi: 10.1172/JCI38660
[12]	Rajab A, Straub V, McCann LJ, et al. Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations[J]. PLoS Genet, 2010, 6(3):e1000874. doi: 10.1371/journal.pgen.1000874
[13]	Zheng YJ, Lee S, Liang XL, et al. Suppression of PTRF alleviates the polymicrobial Sepsis induced by cecal ligation and puncture in mice[J]. J Infect Dis, 2013, 208(11):1803-1812. doi: 10.1093/infdis/jit364
[14]	Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary[J]. Neuro-oncology, 2021, 23(8):1231-1251. doi: 10.1093/neuonc/noab106
[15]	Huang K, Fang C, Yi KK, et al. The role of PTRF/Cavin1 as a biomarker in both glioma and serum exosomes[J]. Theranostics, 2018, 8(6):1540-1557. doi: 10.7150/thno.22952
[16]	Guo Q, Guan GF, Cheng W, et al. Integrated profiling identifies caveolae-associated protein 1 as a prognostic biomarker of malignancy in glioblastoma patients[J]. CNS Neurosci Ther, 2019, 25(3):343-354. doi: 10.1111/cns.13072
[17]	Crivii CB, Boșca AB, Melincovici CS, et al. Glioblastoma microenvironment and cellular interactions[J]. Cancers (Basel), 2022, 14(4):1092. doi: 10.3390/cancers14041092
[18]	Pu WJ, Nassar ZD, Khabbazi S, et al. Correlation of the invasive potential of glioblastoma and expression of caveola-forming proteins caveolin-1 and CAVIN₁[J]. J Neurooncol, 2019, 143(2):207-220. doi: 10.1007/s11060-019-03161-8
[19]	Pu WJ, Qiu JW, Nassar ZD, et al. A role for caveola-forming proteins caveolin-1 and CAVIN1 in the pro-invasive response of glioblastoma to osmotic and hydrostatic pressure[J]. J Cell Mol Med, 2020, 24(6):3724-3738. doi: 10.1111/jcmm.15076
[20]	Yi KK, Zhan Q, Wang QX, et al. PTRF/cavin-1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2[J]. Neuro-oncology, 2021, 23(3):387-399. doi: 10.1093/neuonc/noaa255
[21]	Wang ZX, Tang WJ, Yuan JG, et al. Integrated analysis of RNA-binding proteins in glioma[J]. Cancers, 2020, 12(4):892. doi: 10.3390/cancers12040892
[22]	Yi KK, Cui XT, Liu X, et al. PTRF/cavin-1 as a novel RNA-binding protein expedites the NF-κB/PD-L1 axis by stabilizing lncRNA NEAT1, contributing to tumorigenesis and immune evasion in glioblastoma[J]. Front Immunol, 2022, 12:802795. doi: 10.3389/fimmu.2021.802795
[23]	Yasaswi PS, Shetty K, Yadav KS. Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy[J]. J Control Release, 2021, 336:549-571. doi: 10.1016/j.jconrel.2021.07.003
[24]	Wang X, Liu TZ, Bai YF, et al. Polymerase I and transcript release factor acts as an essential modulator of glioblastoma chemoresistance[J]. PLoS One, 2014, 9(4):e93439. doi: 10.1371/journal.pone.0093439
[25]	Bai L, Lyu Y, Shi GY, et al. Polymerase I and transcript release factor transgenic mice show impaired function of hematopoietic stem cells[J]. Aging, 2020, 12(20):20152-20162. doi: 10.18632/aging.103729
[26]	Huang WJ, Wu K, Wu RY, et al. Bioinformatic gene analysis for possible biomarkers and therapeutic targets of hypertension-related renal cell carcinoma[J]. Transl Androl Urol, 2020, 9(6):2675-2687. doi: 10.21037/tau-20-817
[27]	Zhao YB, Wang YF, Zhao EY, et al. PTRF/CAVIN1, regulated by SHC₁ through the EGFR pathway, is found in urine exosomes as a potential biomarker of ccRCC[J]. Carcinogenesis, 2020, 41(3):274-283. doi: 10.1093/carcin/bgz147
[28]	Yeh HC, Margulis V, Singla N, et al. PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy[J]. Urol Oncol, 2020, 38(5):496-505. doi: 10.1016/j.urolonc.2019.11.010
[29]	Wu Y, Shen QW, Chen XY, et al. miR-1301-3p promotes the proliferation and migration of lung cancer cells via direct repression of polymerase I and transcript release factor[J]. Oncol Lett, 2020, 20(6):286.